Skip to main content
Clinical Trials/NCT06535360
NCT06535360CompletedPhase 4

Improving Efficacy and Safety of Pathogen Inactivation Strategies for Platelet Transfusion in Cardiac Surgical Patients on Cardiopulmonary Bypass

University of Maryland, Baltimore1 site in 1 country150 target enrollmentStarted: September 1, 2020Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Phase 4
Status
Completed
Enrollment
150
Locations
1
Primary Endpoint
Change in Maximum Amplitude (MA) of thromboelastography (TEG)

Study Overview

Brief Summary

This is a prospective randomized clinical trial designed to determine the hemostatic ability of pathogen reduced platelet, when compared to non-pathogen reduced platelets suspended in platelet additive solution.

Detailed Description

The safety and efficacy of pathogen reduced (PRT) platelets (PLTs) have been investigated in several controlled clinical studies. Most of these clinical studies evaluated the efficacy of PRT PLTs during prophylactic transfusion evaluating post-transfusion platelet count increments, rather than platelet function during bleeding episodes. During massive transfusion events and immediate resuscitation, PLT transfusion is recognized as an important determinant of a positive patient outcome. PLT transfusion is important to control bleeding in patients undergoing cardiac surgery on cardiopulmonary bypass because cardiopulmonary bypass alters platelet function. Thus, transfusion of functional platelets is required to control bleeding post-operatively. In this context, the investigators propose to investigate whether efficient hemostasis associated with platelet transfusion differs with the use of pathogen reduced PRT PLTs compared to non-pathogen reduced PLTs that are suspended in platelet additive solution.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Age > 18 years
  • •Preoperative evaluation for risk of transfusion: platelet count < 200,000/mcl, OR anticipated time on cardiopulmonary bypass > 90 min, OR complex cardiac surgery, OR use of preoperative antiplatelet therapy within 3-5 days of surgery.

Exclusion Criteria

  • •Patient that lack the ability to consent
  • •Patients with the diagnosis of idiopathic thrombocytopenia purpura,
  • •Patient with the diagnosis of heparin-induced thrombocytopenia.

Arms & Interventions

PRT PLTs stored in PAS

Experimental

FDA approved and already used in this patient population tested for non-inferiority

Intervention: Platelet transfusion (Biological)

Non-PRT PLTs stored in platelet additive solution (PAS)

Active Comparator

FDA approved and already used in this patient population

Intervention: Platelet transfusion (Biological)

Outcomes

Primary Outcomes

Change in Maximum Amplitude (MA) of thromboelastography (TEG)

Time Frame: within 60 minutes including blood for TEG testing immediately pre transfusion and blood draw post transfusion

ΔMA observed with platelet transfusion (difference in MA measured within an hour post transfusion to MA measured immediately pre-transfusion)

Secondary Outcomes

  • Chest Tube Drainage(24 hours)
  • Red blood cell units Transfused(Within the first 24 Hrs Following Surgery)
  • Plasma Units Transfused(Within the first 24 Hrs Following Surgery)
  • Platelet Units Transfused(Within the first 24 Hrs Following Surgery)
  • Cryoprecipitate Units Transfused(Within the first 24 Hrs Following Surgery)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Magali Fontaine

Professor of Pathology

University of Maryland, Baltimore

Study Sites (1)

Loading locations...

Similar Trials